INTRODUCTION
The mature human erythrocyte meets its energy requirement primarily from the metabolism of carbohydrates, chiefly glucose, although other monosaccharides can be utilized (1) . Normally 6-8 ,umoles of glucose per g of hemoglobin per hr are broken down to lactate via the EmbdenMeyerhof pathway (2) . In addition a small fraction of the glucose-6-phosphate formed is metabolized via the hexosephosphate pathway yielding reduced nicotinamide adenine dinucleotide phosphate (3) . In spite of its dependence upon glucose for energy production the normal red blood cell has virtually no carbohydrate stores, although there is a minimal concentration of glycogen (4) (5) (6) . It was believed that this glycogen was not actively metabolized (5, 7) but was a vestigal remnant of an immature erythrocyte stage (5) . Nevertheless as all enzymes catalyzing glycogen synthesis and breakdown have now been demonstrated in the erythrocyte (8) (9) (10) (11) (12) it would not be unexpected to find a functional glycogen pathway. However, the minute concentrations of glycogen in the erythrocyte have thus far precluded extensive studies of its metabolism.
In type III glycogen storage disease (GSD) which is characterized by the absence of amylo-1-6-glucosidase in various tissues, including the erythrocyte, there is an abnormally high erythrocyte concentration of glycogen of the limit dextrin type (5) . The relatively high incidence of type III GSD in Israel (13) provided a supply of erythrocytes sufficiently high in glycogen content to make possible an investigation of glycogen metabolism. In addition, advantage was taken of the availability of these cells to compare their overall carbohydrate metabolism with those from normal donors. The results to be presented in this report indicate that there is an active turnover of glycogen in both normal and amylo-1,6-glucosidase-deficient cells. In addition it was observed that the glycogen-rich 'cells utilized glucose at a higher rate than normal cells.
METHODS
The subjects of this study were 17 patients in whom the diagnosis of type III GSD had been made on clinical, biochemical, and enzymatic bases. None of them had abnormal hemoglobin values or elevation of the reticulocyte count or bilirubin levels. In some of the GSD patients erythrocyte life span measured by 'Cr labeling, osmotic fragility, and density distribution (14) was determined and all were found to be within normal limits. The glycogen concentration of these erythrocytes ranged from 200-3000 ,ug/g of hemoglobin with a mean of 1054 Ag/g of hemoglobin (these levels are within the range previously reported by Sidbury, Cornblath, Fisher, and House [5] for GSD type III erythrocytes; normal range 20-134 ,ug/g of hemoglobin). Normal control blood was obtained from physicians and laboratory personnel. The (18) . Hexokinase activity was determined according to Valentine and Oski (19) and phosphoglucomutase by a modification of the method of Bergmeyer for glucose-i-phosphate determination (20) .
Amylo-1,6-glucosidase and phosphorylase were determined according to the procedure of Hers (21) and uridine diphosphoglucose (UDPG) glycogen glucosyltransferase by the method described by Cornblath (8) . a-1,4 Glucan: a-s-i,4 glucan 6-glycosyltransferase was determined by a method described by Larner (22) . Glycogen was recovered from erythrocytes after repeated precipitation of the protein with cold 6% trichloroacetic acid, collection of the supernatant, and precipitation of glycogen in cold 95%o
ethanol after the addition of 0.18% Na2SO4 (23) . Glycogen was determined with diazyme reagent (24) .
For the determination of the incorporation of glucose-14C into glycogen the incubation mixture was removed after the incubation, nonlabeled carrier glycogen added, and the glycogen precipitated with cold trichloroacetic acid as described by Sidbury (5). Parallel incubations without erythrocytes revealed no nonspecific glucose-glycogen exchange. Analysis of the distribution of the glucose in the outer branches and inner core of the glycogen was carried out by 8-amylolysis (25) . The production of '4CO2 from glucose was studied by incubating the erythrocytes with the appropriate reaction mixture in sealed vials equipped with center wells containing 0.5 ml of 15% KOH absorbed on No. 1 Whatman filter paper. After the incubation 0.4 ml of 1 N H2SO4 was inj ected into the incubation mixture and the vial shaken for 1 additional hr. The "4C absorbed on the filter paper was then counted. All radioactivity was assayed in a Tri-Carb liquid scintillation counter utilizing a gel for equal dispersion of the radioisotope (26) .
Various coenzymes and adenosine triphosphate were obtained from Boehringer and Sons, Mannheim, Germany or Sigma Chemicals, St. Louis, Mo. Enzymes were obtained from Boehringer and Sons, diazyme from Miles Chemical Corporation, Elkhart, Ind.
RESULTS
The incorporation of glucose-U-14C into glycogen in the erythrocytes from patients with type III GSD was first studied and found to be linear over a period of 3 hr. To further demonstrate the active metabolism of erythrocyte glycogen, red blood cells taken from both normal subjects and patients suffering from type III GSD were incubated for 2 hr with glucose-U-14C. The results, shown in Table I , indicate that both types of erythrocytes incorporate glucose into glycogen at the same rate. Subsequently a portion of the cells was washed and reincubated in the same medium except that unlabeled glucose was present. This resulted in a disappearance of a major portion of the labeled glucosyl units of the glycogen from both types of cells (Table I) . Further insight into the breakdown of glycogen was provided by incubating the glycogen-rich cells in the absence of Table I except that glucose was omitted. Incubation conditions: as in Table I. bation period a shift of labeled glucosyl units from the periphery was reflected by the increasing percentage of radioactivity found in the limit dextrin fraction of the glycogen as the experiment progressed.
The activities of the various enzymes involved ln glycogen metabolism were compared in normal and glycogen-rich erythrocytes. The data presented in Table III indicate that, as expected, there was virtually no amylo-1,6-glucosidase activity in any of the cells from subjects suffering from type III GSD. No difference was noted in the activities of hexokinase, phosphoglucomutase, UDPG glycogen glucosyltransferase or a-1,4 glucan: a-1,4 glucan 6-glycosyltransferase (branching enzyme). However, a significant increase in activity of phosphorylase was found in the erythrocytes from patients suffering from type III GSD.
The rates of glucose utilization and lactate production in normal and glycogen-rich cells were compared. The results, shown in Table IV indicate that the rate of glucose utilization by erythrocytes from patients suffering from type III GSD is significantly greater than that seen with the normal erythrocytes. The relatively higher rate of glucose utilization by the glycogen-rich cells occurred at medium inorganic phosphate levels ranginf from 3-50 mmoles/liter although the difference was more striking at higher phosphate concentrations.' However, the increased glucose utilized is not recovered as lactate, which is similar in the two types of cells and in the normal erythrocyte accounts for about 85%o of the glucose utilized. The possibility that the increased glucose utilization noted in the glycogen-rich erythrocyte might reflect an increase in the oxidation of glucose via the hexose monophosphate shunt was investigated in the presence and absence of methylene blue. Production of 14CO2 from glucose-1-14C was used as an indication of shunt activity. The results shown in Table V, indicate that 14CO2 production by cells from the type III GSD patients is significantly greater than controls when methylene blue is added. Even in the absence of the electron acceptor there is an indication that the rate of 14CO2 is higher in the glycogen-rich cells although the difference is not statistically significant.
DISCUSSION
The evidence accumulated in this report leaves no doubt that the erythrocyte maintains an active glycogen metabolism. It has been demonstrated that the glucose-14C is both incorporated into and via the UDPG glycogen synthetase pathway or is caused by a reversal of the phosphorylase reaction is irrelevant, since in both instances active glycogen metabolism would result. However, in view of the presence of glycogen synthetase and the fact that UDPG is formed in erythrocytes, e.g., in the metabolism of galactose, it seems likely that the synthetase-catalyzed pathway is utilized in the erythrocytes. Whereas glycogen synthesis occurs normally in amylo-1,6-glucosidase-deficient cells, breakdown cannot proceed beyond the branch point and is, therefore, limited to peripheral tiers only. Thus the observed decrease in radioactivity of the peripheral tiers and concomitant increase in activity of the central core as a function of time during incubation of the glycogen-rich erythrocytes with glucose-U-14C can be readily explained as follows: there is an elongation of peripheral tiers which, after attaining a certain length normally form new branches. Since during glycogenolysis hydrolysis cannot proceed beyond the branch points in view of the absence of amylo-1,6-glucosidase, radioactive glucosyl units will be trapped in the inner core. This also explains the increased accumulation of the limit dextrin type glycogen in the cells from patients with type III GSD. Because of the small amount of glycogen present in normal erythrocytes it was not possible to carry out similar studies of the distribution and rearrangement of labeled glucosyl units with time in these cells.
The finding that the glycogen-rich cells utilized glucose at a greater rate than normal erythrocytes was surprising, especially since the rate of incorporation of glucose into glycogen did not differ between the two types of cells. Since the excess glucose utilized by the glycogen-rich cells does not appear as lactate, the carbon atoms must be trapped in some other glycolytic intermediate. The increase in oxidation of glucose to CO2 by the diseased cells even if significant is inadequate to account for the excess glucose disappearance.
It is evident from these studies that the metabolic abnormalities encountered in erythrocytes of patients with type III GSD are not restricted to abnormal glycogen accumulation but involve alterations of carbohydrate metabolism including active glycogen turnover and in the metabalic controls of glucose utilization at a level still to be determined.
